The CorEvitas Psoriasis (PSO) Registry
Recruiting · NCT02707341 · Observational (researchers observe without assigning treatment) · Lead sponsor: CorEvitas
View the official record on ClinicalTrials.gov →What this trial is about
The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- and none of the
Exclusion criteria
- listed below.
- Inclusion Criteria:
- The patient must:
- Have been diagnosed with psoriasis by a dermatologist.
- Be at least 18 years of age or older.
- Be willing and able to provide written consent for participation in the registry.
- Be willing and able to provide Personally Identifiable Information (PII) that includes the following types of personal information at a minimum: 1) Full Name and 2) Date of Birth.
- Meet one of the following criteria.
- Have started on or switched to a systemic psoriasis treatment within the previous 12 months†▲:
- Exclusion Criteria:
- \. Patient is participating in or planning to participate in a double-blind randomized of a psoriasis drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.
Where it is running
1 location listed across 1 US state.
- Study site - Waltham, Massachusetts, United States